Evox Therapeutics
has developed its DeliverEX platform specifically to engineer and load exosomes with RNA payloads and gene-editing tools including CRISPR-Cas9 components for targeted delivery to difficult-to-reach tissue.
- Country
- United Kingdom
engineered-exosomes
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Exosome therapy & extracellular vesicles | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.